{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:35:15Z","timestamp":1784180115953,"version":"3.55.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01753-7","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:30:42Z","timestamp":1775755842000},"page":"3235-3244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perceptions and Experiences of Patients Across All Skin Tones Living with Psoriasis in Canada"],"prefix":"10.1007","volume":"16","author":[{"given":"H. Chih-ho","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frankie","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omair","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Park-Wyllie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"1753_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180","volume":"8","author":"G Damiani","year":"2021","unstructured":"Damiani G, Bragazzi NL, Aksut CK, et al. The global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 study. Front Med. 2021;8:743417.","journal-title":"Front Med"},{"key":"1753_CR2","doi-asserted-by":"crossref","unstructured":"Greb JE, Goldminz AM, Elder JT,et al. Psoriasis.  Nat Rev Dis Primers. 2016;24(2):16082.","DOI":"10.1038\/nrdp.2016.82"},{"issue":"1","key":"1753_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.04.139","volume":"84","author":"S Mehrmal","year":"2021","unstructured":"Mehrmal S, Uppal P, Nedley N, Giesey RL, Delost GR. The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: a systematic analysis from the Global Burden of Disease Study 2017. J Am Acad Dermatol. 2021;84(1):46\u201352.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1753_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","volume":"21","author":"A Raharja","year":"2021","unstructured":"Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med. 2021;21(3):170\u20133.","journal-title":"Clin Med"},{"issue":"11","key":"1753_CR5","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s13555-022-00811-0","volume":"12","author":"G Yadav","year":"2022","unstructured":"Yadav G, Yeung J, Miller-Monthrope Y, et al. Unmet need in people with psoriasis and skin of color in Canada and the United States. Dermatol Ther. 2022;12(11):2401\u201313.","journal-title":"Dermatol Ther"},{"key":"1753_CR6","unstructured":"Statistics Canada. AnnualdDemographic estimates: Canada, provinces and territories. 2021. Ottawa: Statistics Canada; 2021. Catalogue no. 91-215-X. https:\/\/www150.statcan.gc.ca\/n1\/pub\/91-215-x\/91-215-x2021001-eng.htm. Accessed 12 Aug 2025"},{"issue":"11","key":"1753_CR7","first-page":"16","volume":"7","author":"AF Alexis","year":"2014","unstructured":"Alexis AF, Blackcloud P. Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. J Clin Aesthet Dermatol. 2014;7(11):16\u201324.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"10","key":"1753_CR8","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/ijd.17236","volume":"63","author":"V Wan","year":"2024","unstructured":"Wan V, Habibi A, Mija LA, Abdi P, Selvakumar R, Mukovozov I. Disparities and barriers to the access of biologics in moderate-to-severe adult psoriasis. Int J Dermatol. 2024;63(10):1293\u2013301.","journal-title":"Int J Dermatol"},{"issue":"8","key":"1753_CR9","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/j.jid.2018.12.032","volume":"139","author":"J Takeshita","year":"2019","unstructured":"Takeshita J, Eriksen WT, Raziano VT, et al. Racial differences in perceptions of psoriasis therapies: implications for racial disparities in psoriasis treatment. J Invest Dermatol. 2019;139(8):1672-9.e1.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1753_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/bjd.19876","volume":"185","author":"WT Hodges","year":"2021","unstructured":"Hodges WT, Bhat T, Raval NS, et al. Biologics utilization for psoriasis is lower in Black compared with White patients. Br J Dermatol. 2021;185(1):207\u20139.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1753_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamadermatol.2024.5103","volume":"161","author":"A Alexis","year":"2025","unstructured":"Alexis A, McMichael A, Vashi N, et al. Improving diversity in a novel psoriasis study: VISIBLE as a framework for clinical trial quality improvement. JAMA Dermatol. 2025;161(3):256\u201364.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1753_CR12","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1001\/jamadermatol.2025.1836","volume":"161","author":"A Alexis","year":"2025","unstructured":"Alexis A, McMichael A, Soung J, et al. Guselkumab for moderate to severe psoriasis across all skin tones: Cohort A of the VISIBLE randomized clinical trial. JAMA Dermatol. 2025;161(9):901\u201311.","journal-title":"JAMA Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01753-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01753-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01753-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:53:54Z","timestamp":1780584834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01753-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1753"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01753-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H Chih-ho Hong has been an investigator for and\/or a consultant for and\/or received honorarium from: Abbvie, Amgen, Arcutis, ASLAN pharmaceutics, Bausch Health, Biocon, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Celltrion, Cutanea, Dermira, Dermavant, DS Biopharma, Eli-Lilly, Evelo Biosciences, Galderma, GSK, Incyte, Iqvia, JAMP Pharma, Janssen, Leo Pharma, Medimmune, Merck, Mirimar, Novartis, Organon, Oruka, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, Takeda and UCB. Marissa Joseph has received honoraria for consulting and\/or speaking from: AbbVie, Amgen, Arcutis, Bausch, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galderma, Incyte, Janssen, Kenvue, Leo, Loreal, Novartis, Pierre Fabre, Pfizer, Sanofi Genzyme, Sun Pharma and UCB. Frankie Tai, Omair Lakhani and Laura Park-Wyllie are employees of Johnson & Johnson at the time of the study and manuscript development and may own stock or stock options in Johnson & Johnson. Saad Mirza was an employee of Johnson & Johnson at the time of the study and manuscript development and may own stock or stock options in Johnson & Johnson. Saad Mirza has no current institutional affiliation. Tessa Carr was a PharmD student and intern at Johnson & Johnson at the time this work was conducted and is currently a PharmD student at the University of Toronto; she reports no additional conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethics committee, institutional review board (IRB) or research ethics board (REB) approval was not required for this study as it was conducted as an online quantitative market research survey and did not involve interventions with human subjects. Accordingly, no ethics committee name(s), reference number(s) or IRB approval number are available. The study was conducted in accordance with applicable legal requirements and industry standards for market research. All participants provided informed consent to participate prior to inclusion in the study. All responses were fully anonymized, and no identifiable personal information was collected; therefore, consent to publish identifiable information was not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}